Garde-Noguera J, et al. - In this retrospective review of non-small-cell lung cancer (NSCLC) patients treated with nivolumab, the following were found to be associated with poorer prognosis: poor performance status, short period of time since the previous treatment, and more than one metastatic location.

• Researchers retrospectively reviewed NSCLC patients treated with nivolumab.
• They analyzed the following variables: age, sex, stage, performance status (PS), location of metastases, presence of tumour-related symptoms and comorbidities, number of metastasis locations, previous chemotherapy, anti-angiogenic and radiotherapy treatments, and analytical data from the standard blood count and biochemistry.

• Data reported that a total of 175 patients were included, median age was 61.5 years, 73.1% were men, 77.7% were ECOG-PS 0–1, and 86.7% were included with stage IV disease.
• In 77.1%, non-squamous histology was detected.
• Nivolumab was administered to 65 in second line (37.1%).
• Brain metastasis, liver metastasis and more than one metastatic location were found in 38 patients (22%), 39 (22.3%), and 126 (72%), respectively.
• As per data, the ORR was 15.7% with median progression free survival (PFS) 2.8 months and median OS 5.81 months.
• The following were found to be associated with better response: stage III vs IV and time since the beginning of the previous line of treatment ≥ 6 vs < 6 months.
• In multivariable analysis, the following were found to be independently associated with shorter OS: PS 2, time since the previous line of treatment < 6 vs ≥ 6 months, and more than one metastatic location (7.8 vs 2.7 months, 11.2 vs 4.6 months, and 9.4 vs 5.1 month).
• Furthermore, in multivariable analysis, time since the previous treatment < 6 vs ≥ 6 months and more than one metastatic location were found to be independently related to shorter PFS (4.3 vs 2.3 months and 4.7 vs 2.3 months).